Mirabegron

From Wikipedia, the free encyclopedia

Template:Short description Template:DMCA Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Mirabegron
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesMyrbetriq, Betanis, Betmiga, others
Other namesYM-178
AHFS/Drugs.comMonograph
MedlinePlusa612038
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: B3
Routes of
administration		By mouth
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Bioavailability29–35%[4]
Protein binding71%[4]
MetabolismLiver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[4]
Elimination half-life50 hours[4]
ExcretionUrine (55%), faeces (34%)[4]
Identifiers
  • 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC21H24N4O2S
Molar mass396.51 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N
  • InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
  • Key:PBAPPPCECJKMCM-IBGZPJMESA-N
Data page
Template:Infobox drug/data page link

Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder.[5] Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine.[6] It is taken by mouth.[5]

Common side effects include high blood pressure, headaches, and urinary tract infections.[5] Other significant side effects include urinary retention, irregular heart rate, and angioedema.[5][7] It works by activating the β3 adrenergic receptor in the bladder, resulting in its relaxation.[5][7]

Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012.[8][9][3] In 2023, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[10][11] It is available as a generic medication.[12]

Medical uses

Mirabegron is used is in the treatment of overactive bladder.[13][4][2][1] It works equally well to antimuscarinic medication such as solifenacin or tolterodine.[6][3] In the United Kingdom it is less preferred to these agents.[7]

Mirabegron is also indicated to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.[13]

Adverse effects

Adverse effects by incidence:[4][2][1]

Very common (>10% incidence) adverse effects include:

Common (1–10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:

Research

As a selective beta-3 adrenergic agonist, mirabegron does not cause the cardiovascular adverse effects of other adrenergic agonists that are active at the beta-1 and beta-2 adrenergic receptors. Beta-3 adrenergic agonists activate brown adipose tissue (BAT) and increase energy expenditure, leading to research interest in their development as weight loss drugs.[14] A combination of mirabegron and metformin was studied in mice and caused greater weight loss than either drug alone.[15] A human study in obese individuals found an increase in insulin sensitivity but no significant weight change, which was hypothesized to be due to low levels of BAT in obese humans and/or the low dose of mirabegron used in the study.[16]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content."Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Archived from the original on 2 April 2015. Retrieved 17 November 2013.
  2. ^ a b c Page Module:Citation/CS1/styles.css has no content."Myrbetriq- mirabegron tablet, film coated, extended release". DailyMed. Retrieved 27 March 2021.
  3. ^ a b c Page Module:Citation/CS1/styles.css has no content."Betmiga EPAR". European Medicines Agency. 17 September 2018. Retrieved 28 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ a b c d e f g Page Module:Citation/CS1/styles.css has no content."mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
  5. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."Mirabegron Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
  6. ^ a b Page Module:Citation/CS1/styles.css has no content."[93] Are claims for newer drugs for overactive bladder warranted?". Therapeutics Initiative. 22 April 2015. Retrieved 17 March 2019.
  7. ^ a b c Page Module:Citation/CS1/styles.css has no content.British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382.
  8. ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Myrbetriq (mirabegron) Extended Release Tablets NDA #202611". U.S. Food and Drug Administration (FDA). 10 August 2012. Retrieved 28 April 2020.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, et al. (April 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opinion on Drug Discovery. 9 (4): 433–448. doi:10.1517/17460441.2014.892923. PMID 24559030. S2CID 26424400.
  10. ^ Page Module:Citation/CS1/styles.css has no content."The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
  11. ^ Page Module:Citation/CS1/styles.css has no content."Mirabegron Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 20 August 2025.
  12. ^ Page Module:Citation/CS1/styles.css has no content."2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  13. ^ a b Page Module:Citation/CS1/styles.css has no content."FDA Approves New indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients". U.S. Food and Drug Administration (FDA) (Press release). 25 March 2021. Archived from the original on 25 March 2021. Retrieved 26 March 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Hainer V (November 2016). "Beta3-adrenoreceptor agonist mirabegron - a potential antiobesity drug?". Expert Opinion on Pharmacotherapy. 17 (16): 2125–2127. doi:10.1080/14656566.2016.1233177. PMID 27600952. S2CID 1308773.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Zhao XY, Liu Y, Zhang X, Zhao BC, Burley G, Yang ZC, et al. (April 2023). "The combined effect of metformin and mirabegron on diet-induced obesity". MedComm. 4 (2): e207. doi:10.1002/mco2.207. PMC 9928947. PMID 36818016.
  16. ^ Page Module:Citation/CS1/styles.css has no content.Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, et al. (October 2020). "The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors". Pharmacology Research & Perspectives. 8 (5): e00643. doi:10.1002/prp2.643. PMC 7437350. PMID 32813332.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Adrenergics Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

Retrieved from "https://cosmopedia.co/index.php?title=Mirabegron&oldid=11542440"